A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis

Bone Marrow Transplantation

Volumn 44, Issue 5, 2009, Pages 317-320

  Gupta, Vikas ^a   Kroger N ^b   Aschan, J ^c   Xu, W ^a   Leber, B ^d   Dalley, C ^e   Sabloff, M ^f   Lipton, J H ^a   Messner, H ^a   Brune, M ^g  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d MCMASTER UNIVERSITY   (Canada)

^e ST GEORGE S HOSPITAL   (United Kingdom)

^f UNIVERSITY OF OTTAWA   (Canada)

^g SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; MELPHALAN; METHOTREXATE; THYMOCYTE ANTIBODY;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CONVENTIONAL INTENSITY CONDITIONING; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; MALE; MORTALITY; MYELOFIBROSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; RELAPSE; RETROSPECTIVE STUDY;

ADULT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; PRIMARY MYELOFIBROSIS; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 70349160401     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.10     Document Type: Article

References (10)

1. Guardiola P, Anderson JE, Bandini G, Cervantes F, Runde V, Arcese W et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: A European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 1999; 93: 2831-2838.
2. Deeg HJ, Gooley TA, Flowers ME, Sale GE, Slattery JT, Anasetti C et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003; 102: 3912-3918.
3. Daly A, Song K, Nevill T, Nantel S, Toze C, Hogge D et al. Stem cell transplantation for myelofibrosis: A report from two Canadian centers. Bone Marrow Transplant 2003; 32: 35-40.
4. Rondelli D, Barosi G, Bacigalupo A, Prchal JT, Popat U, Alessandrino EP et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate-or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005; 105: 4115-4119.
5. Snyder DS, Palmer J, Stein AS, Pullarkat V, Sahebi F, Cohen S et al Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis. Biol Blood Marrow Transplant 2006; 12: 1161-1168.
6. Kroger N, Zabelina T, Schieder H, Panse J, Ayuk F, Stute N et al. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol 2005; 128: 690-697.
7. Merup M, Lazarevic V, Nahi H, Andreasson B, Malm C, Nilsson L et al Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens. Br J Haematol 2006; 135: 367-373.
8. Barosi G, Ambrosetti A, Finelli C, Grossi A, Leoni P, Liberato NL et al. The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Br J Haematol 1999; 104 730-737.
9. Gupta V, Daly A, Lipton JH, Hasegawa W, Chun K, Kamel-Reid S et al Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older. Biol Blood Marrow Transplant 2005; 11: 764-772.
10. Kroeger N, Holler E, Kobbe G, Bornhaeuser M, Schwerdtfeger R, Nagler A et al. Dose-reduced conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis. Results from a Multicenter Prospective Trial of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood (ASH Annual Meeting Abstracts) 2007; 110: 683.